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cultural, and economic changes and female-controlled pre-
vention, such as microbicides.
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Impact of HIV on Women in
the United States
In the United States, AIDS was first reported in women
in 1981 (1), and the percentage of AIDS cases in women
has continued to increase, accounting for an estimated
26% of new AIDS diagnoses in 2002 (2). Since 1998,
deaths among women with AIDS in the United States have
remained stable at an estimated 4,000 (2).
Epidemiologic Features of HIV in 
Women, United States
Data from 29 states with confidential name-based HIV
reporting since 1998 were used to describe the status of
HIV disease among women from 1999 through 2002. HIV
diagnoses were defined as diagnoses of HIV infection
regardless of AIDS diagnosis status. This diagnosis
includes persons with a diagnosis of HIV infection only,
HIV infection and later AIDS diagnosis, or concurrent
diagnoses of HIV infection and AIDS.
From 1999 through 2002, an estimated 101,872 HIV
diagnoses were reported from 29 states: 72,007 (70.7%) in
men and 29,865 (29.3%) in women. Among women,
71.9% were non-Hispanic blacks, 18.2% were non-
Hispanic whites, 8.4% were Hispanics, 0.6% were
American Indian/Alaska Natives, and 0.4% were
Asian/Pacific Islanders. The two principal modes of HIV
exposure for women were heterosexual contact and injec-
tion drug use, accounting for 77.7% and 20.5% of diag-
noses among women, respectively. Women were
diagnosed with HIV at younger ages than men. For the 4-
year period, 31.3% of women with HIV were in the 13- to
29-year age group compared with 19.9% of men in the
same age group. HIV diagnosis rates were consistently
higher among non-Hispanic black women compared with
women from other racial and ethnic groups for all 4 years.
Prevention Strategies for Women
In 2003, the Centers for Disease Control and
Prevention (CDC) introduced the Advancing HIV
Prevention (AHP) initiative (3). AHP aims to reduce barri-
ers to early diagnosis of HIV infection, increase access to
quality medical care and treatment, and provide ongoing
prevention services for persons living with HIV. AHP
incorporates four priority strategies: make voluntary HIV
testing a routine part of medical care, implement new mod-
els for diagnosing HIV infections outside of the medical
settings, prevent new infections by working with persons
diagnosed with HIV and their partners, and decrease peri-
natal transmission.
Clinical Care of Women with HIV
HIV-infected women may be at increased risk for med-
ical problems and metabolic changes. Studies have shown
that HIV-positive women were more likely to develop gen-
ital warts and cervical intraepithelial neoplasia (4) and
were at increased risk for viral infections (5). According to
one study, HIV-positive women were 80% more likely to
be anemic than HIV-positive men (6). Compared with
HIV-negative controls, women with HIV were more likely
to have elevated triglycerides and insulin levels (7) and
decreased bone mineral density (8).
Determining when to initiate antiretroviral therapy for
HIV-infected women is based on CD4+ T cell count (9).
Because no gender difference exists for initiating or apply-
ing antiretroviral drug regimens, the guidelines for treating
women are the same as those for treating men. Overall,
drug efficacy does not differ by gender in randomized clin-
ical trials. 
For many reasons, women with HIV may avoid HIV
testing and care. Often, women may be stigmatized and
endure discrimination because of their HIV status. Women
are often the primary caregivers for other family members,
which may lead to avoiding or delaying testing and care.
Economic dependence on a spouse or significant other
may also play a role in whether a woman seeks testing and
care. Mistrust of the healthcare system may also exist.
Depression or domestic violence may also affect a
woman's ability to seek needed care for HIV infection.
Incorporating HIV Prevention into Medical Care
In 2003, CDC, the Health Resources and Services
Administration, National Institutes of Health, and the HIV
Medicine Association of the Infectious Diseases Society of
America issued recommendations to assist clinicians in
integrating HIV prevention into primary care for HIV-
infected persons. Providers are encouraged to deliver brief
prevention messages during primary care visits, screen for
HIV risk behaviors and sexually transmitted disease, pro-
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Human Papillomavirus and
Cervical Cancer
Though cervical cancer is highly curable when detect-
ed early, it remains one of the leading causes of cancer
death in women worldwide. Early detection is effective
because the precursor lesions evolve slowly into invasive
cancer, typically over a period of >10 years. These precur-
sor lesions (dysplasias or cervical intraepithelial neo-
plasias [CIN]) are detected with cervical cytology
screening, the Pap smear. In every country where a Pap
smear screening program has been introduced, rates of cer-
vical cancer have been substantially reduced. The discov-
ery that human papillomaviruses (HPV) are etiologically
linked with cervical cancer has led to efforts to apply this
knowledge to improve cervical cancer screening and to
potentially prevent cervical cancer through vaccination.
HPV and Cervical Cancer
HPV is not a single virus but a family of closely relat-
ed viruses, each designated as a type, numbered in order of
discovery. Typing is based on nucleic acid sequencing.
More than 100 HPV types are known to exist, and at least
30 can be detected in the anogenital tract. No simple in
vitro culture methods are available for identifying it, and
serologic testing is insensitive. Techniques for identifying
the virus are based on nucleic acid detection, either direct
hybridization or after amplification. HPV types associated
with malignancies are referred to as high-risk types, and
those associated with warts (condylomas) are rarely found
in cancers and are called low-risk types.
Sexual transmission is the dominant mechanism for
acquiring genital HPV. Infection is usually transient and
not associated with symptoms. An estimated 80% of sexu-
ally active women have been exposed. Studies have detect-
ed HPV in  90% of cancers worldwide, and plausible
biologic mechanisms can explain oncogenesis. The magni-
tude of the risk association between HPV and cervical can-
cer is greater than that for smoking and lung cancer.
However, infection alone is insufficient to cause cancer,
and additional factors are required for neoplasia.
HPV Vaccination as a Prevention Strategy
One investigational quadrivalent vaccine includes types
6, 11, 16, and 18. HPV-16 and HPV-18 (high-risk types)
are found in 25% of all CIN I lesions and 70% of CIN II/III
and anogenital cancers. HPV-6 and HPV-11 (low-risk
types) are found in 25% of CIN I lesions and 90% of
anogenital warts. Therefore a prophylactic vaccine against
these four types would substantially reduce HPV-related
disease.
Vaccine candidates have been evaluated in animal mod-
els of papillomavirus infection. The L1 protein of HPV is
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